Reference
Nerich V, et al. Cost-Effectiveness Analysis of Tyrosine Kinase Inhibitors for Patients with Advanced Gastrointestinal Stromal Tumors. Clinical Drug Investigation : 24 Sep 2016. Available from: URL: http://doi.org/10.1007/s40261-016-0463-2
Rights and permissions
About this article
Cite this article
Imatinib + sunitinib good value for money in GISTs. PharmacoEcon Outcomes News 763, 19 (2016). https://doi.org/10.1007/s40274-016-3432-3
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40274-016-3432-3